Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Lifted by Silvercrest Asset Management Group LLC

Silvercrest Asset Management Group LLC increased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 4.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 374,958 shares of the biopharmaceutical company’s stock after buying an additional 16,033 shares during the quarter. Silvercrest Asset Management Group LLC owned 0.13% of Amicus Therapeutics worth $4,417,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Wellington Management Group LLP grew its stake in Amicus Therapeutics by 101.9% in the fourth quarter. Wellington Management Group LLP now owns 15,190,024 shares of the biopharmaceutical company’s stock valued at $215,546,000 after purchasing an additional 7,666,335 shares in the last quarter. Norges Bank purchased a new position in Amicus Therapeutics in the fourth quarter valued at about $35,915,000. Blackstone Inc. purchased a new position in Amicus Therapeutics in the fourth quarter valued at about $35,008,000. Healthcare of Ontario Pension Plan Trust Fund grew its stake in Amicus Therapeutics by 583.4% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,176,600 shares of the biopharmaceutical company’s stock valued at $25,640,000 after purchasing an additional 1,858,100 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Amicus Therapeutics by 5.0% in the fourth quarter. Vanguard Group Inc. now owns 28,492,486 shares of the biopharmaceutical company’s stock valued at $404,308,000 after purchasing an additional 1,360,613 shares in the last quarter.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 6,100 shares of the company’s stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,866,540. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $10.07, for a total value of $75,525.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,928,605.78. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Bradley L. Campbell sold 6,100 shares of the company’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $10.00, for a total value of $61,000.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at $8,866,540. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Guggenheim upgraded Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Tuesday, May 14th. UBS Group decreased their price target on Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Morgan Stanley decreased their price target on Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Friday, May 10th. Bank of America decreased their price target on Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Finally, Wells Fargo & Company initiated coverage on Amicus Therapeutics in a research note on Thursday, May 30th. They set an “overweight” rating and a $18.00 price target for the company. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.57.

Amicus Therapeutics Stock Down 0.8 %

Shares of NASDAQ FOLD traded down $0.08 during trading hours on Tuesday, hitting $10.03. 1,168,020 shares of the company’s stock were exchanged, compared to its average volume of 2,809,205. Amicus Therapeutics, Inc. has a 1-year low of $9.02 and a 1-year high of $14.57. The company has a debt-to-equity ratio of 2.97, a current ratio of 3.03 and a quick ratio of 2.61. The company’s 50-day moving average price is $10.09 and its 200-day moving average price is $11.21.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.04. The business had revenue of $110.40 million during the quarter, compared to analysts’ expectations of $111.19 million. Amicus Therapeutics had a negative return on equity of 77.08% and a negative net margin of 34.73%. The firm’s revenue was up 27.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.18) EPS. As a group, research analysts anticipate that Amicus Therapeutics, Inc. will post -0.12 earnings per share for the current fiscal year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.